

Martin Aringer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9322508/martin-aringer-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

12,779
citations

46
h-index

112
g-index

242
ext. papers

16,619
ext. citations

6.1
avg, IF

6.06
L-index

#	Paper	IF	Citations
147	A glimpse into the future of systemic lupus erythematosus.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221086719	3.8	2
146	Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib.. <i>British Journal of Dermatology</i> , 2022 ,	4	0
145	Rheumatologie 2021. <i>Orthopädie Und Unfallchirurgie Up2date</i> , 2021 , 16, 607-625	0.1	
144	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
143	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2021 ,	3.9	2
142	Frauen und Gicht Eine diagnostische Herausforderung. <i>Aktuelle Rheumatologie</i> , 2021 , 46, 62-69	0.1	0
141	New lupus criteria: a critical view. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 205-210	5.3	3
140	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. <i>Rheumatology</i> , 2021 , 60, 2976-2978	3.9	1
139	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021 , 60, 5318-5328	3.9	1
138	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e328-e336	14.2	14
137	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1175-1182	2.4	2
136	Systemic Lupus Erythematosus Classification and Diagnosis. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 501-511	2.4	1
135	Response to: Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus by Wang. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e193	2.4	
134	Response to: New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion by Sacre. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e191	2.4	2
133	Response to: European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view by Infantino. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e189	2.4	21
132	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 671-676	9.5	8
131	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10

130	Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2. <i>Lancet Rheumatology, The</i> , 2021 , 3, e538-e540	14.2	3
129	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Aringer. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	0
128	Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. <i>Rheumatology</i> , 2021 ,	3.9	1
127	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101672	5.3	0
126	Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. <i>Lupus</i> , 2021 , 30, 431-438	2.6	4
125	Diagnosis and Classification of Systemic Lupus Erythematosus 2021 , 51-66		1
124	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 319-328	2.2	1
123	Classifying and diagnosing systemic lupus erythematosus in the 21st century. <i>Rheumatology</i> , 2020 , 59, v4-v11	3.9	23
122	New Criteria for Lupus. <i>Current Rheumatology Reports</i> , 2020 , 22, 18	4.9	18
121	Neue Klassifikationskriterien des SLE: was helfen sie fñdie klinische Diagnose des SLE?. <i>Aktuelle Rheumatologie</i> , 2020 , 45, 299-306	0.1	
120	SLE classification criteria items are not dependent on current activity but may accumulate over time. Response to: Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity? By Teng. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
119	Chemosensory function is decreased in rheumatoid arthritis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020 , 277, 1675-1680	3.5	4
118	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173
117	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 860-861	9.5	
116	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	3.4	851
115	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1404	9.5	
114	Response to: Correspondence on Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities By Ronnelid. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
113	Inflammatory markers in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 110, 102374	15.5	40

112	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 695-696	9.5	1
111	Effector Mechanisms in Autoimmunity 2020 , 319-329		
110	New classification criteria for systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 590-596	5.3	8
109	Treat-to-Target bei systemischem Lupus erythematosus. <i>Karger Kompass Autoimmun</i> , 2020 , 2, 45-51	0	
108	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
107	Gastrointestinal SLE involvement in SLE classification. Response to: 2019 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus by Aringer and Cui. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	16
106	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1820-1826	4.7	16
105	Difference between SLE classification and diagnosis and importance of attribution. Response to: Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients? by Chi. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	3
104	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35
103	New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study. <i>PLoS ONE</i> , 2019 , 14, e0217412	3.7	14
102	Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1329-1338	9.5	42
101	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
100	Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. <i>Arthritis Care and Research</i> , 2019 , 71, 471-481	4.7	26
99	Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019 , 71, 91-98	9.5	60
98	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
97	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
96	FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 2019 ,		3
95	Response to: New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS by Assan. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	

94	Treat to Target in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 537-548	2.4	4
93	EULAR/ACR classification criteria for SLE. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, S14-S17	5.3	27
92	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
91	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 713-714	2.4	2
90	Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell Profiling. <i>Arthritis and Rheumatology</i> , 2019 , 71, 817-828	9.5	4
89	Reply. <i>Arthritis Care and Research</i> , 2019 , 71, 696-697	4.7	1
88	Immunoabsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. <i>Diabetes Care</i> , 2018 , 41, e23-e24	14.6	10
87	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1488-1494	4.7	36
86	Tocilizumab in the treatment of giant cell arteritis. <i>Immunotherapy</i> , 2018 , 10, 465-472	3.8	1
85	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018 , 70, 428-438	4.7	86
84	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018 , 70, 571-581	4.7	74
83	Essential and Optional Drugs for Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018 , 77-96	0.3	
82	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 174	5.7	15
81	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. <i>Rheumatology International</i> , 2018 , 38, 569-577	3.6	25
80	Janus kinase inhibitors clear to land. <i>Rheumatology</i> , 2018 , 57, 1131-1132	3.9	1
79	Systemic sclerosis phase III clinical trials: Hope on the horizon?. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 193-200	2.3	4
78	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
77	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	2.4	1649

76	Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells. <i>Atherosclerosis Supplements</i> , 2017 , 30, 141-148	1.7	2
75	Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis - A Multi-perspective Consensus Study. <i>Zeitschrift Fur Orthopadie Und Unfallchirurgie</i> , 2017 , 155, 539-548	1.1	29
74	Immunoabsorption in Autoimmune Diseases Affecting the Kidney. <i>Seminars in Nephrology</i> , 2017 , 37, 478-487	4.8	12
73	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017 , 377, 317-328	59.2	578
72	Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. <i>Arthritis Care and Research</i> , 2017 , 69, 58-66	4.7	18
71	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	24
70	Januskinaseinhibitoren. <i>Journal Für Mineralstoffwechsel & Muskuloskelettale Erkrankungen</i> , 2017 , 24, 76-80	0.1	
69	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
68	Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 130-136	11.5	108
67	Parvovirus infection in early arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 207-13	2.2	4
66	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015 , 102, 19-24	3.7	11
65	Safety of off-label biologicals in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 243-51	4.1	8
64	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. <i>Journal of Clinical Investigation</i> , 2015 , 125, 413-24	15.9	139
63	Effector Mechanisms in Autoimmunity 2014 , 311-318		1
62	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
61	Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. <i>Rheumatology</i> , 2014 , 53, 1630-8	3.9	56
60	Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review. <i>Arthritis Care and Research</i> , 2014 , 66, 1895-904	4.7	6
59	Innate immune processes in lupus erythematosus. <i>Clinical Immunology</i> , 2013 , 147, 216-22	9	27

58	Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1194-9	2.4	47
57	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013 , 52, 1070-6	3.9	52
56	A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals. <i>Journal of Clinical Rheumatology</i> , 2013 , 19, 241-5	1.1	16
55	Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 213-8	2.2	4
54	Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, S71-4	2.2	10
53	Therapeutic blockade of TNF in patients with SLE-promising or crazy?. <i>Autoimmunity Reviews</i> , 2012 , 11, 321-5	13.6	76
52	Role of interleukin-6 in stress, sleep, and fatigue. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1261, 88-96	6.5	167
51	"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 41, 589-98	5.3	88
50	Interferon signals and monocytic sensitization of the interferon- β signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 400-8		28
49	Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). <i>Journal of Rheumatology</i> , 2012 , 39, 2153-6	4.1	25
48	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
47	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R2	5.7	13
46	TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. <i>Acta Dermato-Venereologica</i> , 2012 , 92, 401-3	2.2	3
45	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
44	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1178-82	2.4	24
43	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1986-90	2.4	22
42	Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. <i>Case Reports in Medicine</i> , 2011 , 2011, 397646	0.7	6
41	Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. <i>New England Journal of Medicine</i> , 2010 , 362, 2431-2	59.2	5

40	Gout--current diagnosis and treatment. <i>Deutsches Arzteblatt International</i> , 2009 , 106, 549-55	51
39	Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009 , 48, 1451-4	3.9 144
38	Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1463-71	80
37	Clinical applications of IFN-β blockade in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 617-619	1.5
36	Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. <i>Arthritis and Rheumatism</i> , 2009 , 61, 21-8	38
35	SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. <i>Nature Genetics</i> , 2008 , 40, 437-42	36.3 563
34	The role of tumor necrosis factor-alpha in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2008 , 10, 202	5.7 109
33	The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. <i>American Journal of Medicine</i> , 2008 , 121, e3-4	2.4 8
32	Understanding deficient elimination of uric acid. <i>Lancet, The</i> , 2008 , 372, 1929-30	40 6
31	Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 411-9	4.1 46
30	Targeted Therapies [Many Ways to (the Peace of) Rome. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008 , 8, 200-206	
29	Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. <i>Arthritis and Rheumatism</i> , 2008 , 50, 1224-31	7
28	Regulatory T cells have anti-inflammatory effects by diluting TNF. <i>Future Rheumatology</i> , 2008 , 3, 231-234	
27	A bridge between interferon-alpha and tumor necrosis factor in lupus. <i>Journal of Rheumatology</i> , 2008 , 35, 1473-6	4.1 15
26	Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 274-9	85
25	Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1287-95	57
24	Mixed connective tissue disease: what is behind the curtain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 1037-49	5.3 22
23	High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 561-2	2.4 2

22	Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon. <i>Autoimmunity</i> , 2007 , 40, 315-21	3	4
21	The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 966-9	2.4	80
20	Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. <i>European Journal of Radiology</i> , 2007 , 62, 437-43	4.7	66
19	Does mixed connective tissue disease exist? Yes. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 411-20, v	2.4	55
18	New treatments for SLE: cell-depleting and anti-cytokine therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 859-78	5.3	71
17	Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 2537-41	9.7	54
16	Engineering anticancer T cells for extended functional longevity. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1019, 178-85	6.5	9
15	Immunoabsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. <i>Wiener Klinische Wochenschrift</i> , 2004 , 116, 716-24	2.3	22
14	Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3161-9		265
13	Periodic fever syndromes--a clinical overview. <i>Vienna Clinical Weekly</i> , 2004 , 31, 8-12		6
12	Characterization and analysis of the proximal Janus kinase 3 promoter. <i>Journal of Immunology</i> , 2003 , 170, 6057-64	5.3	26
11	SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. <i>Arthritis Research</i> , 2003 , 5, 172-7		67
10	Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. <i>Journal of Rheumatology</i> , 2002 , 29, 1430-6	4.1	63
9	Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1721-2		10
8	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000 , 95, 3223-3231	2.2	306
7	Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. <i>Journal of Immunology</i> , 2000 , 164, 4659-64	5.3	144
6	Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. <i>Journal of Immunology</i> , 2000 , 164, 1768-74	5.3	196
5	Ultrasound therapy for calcific tendinitis of the shoulder. <i>New England Journal of Medicine</i> , 1999 , 340, 1533-8	59.2	225

4	Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. <i>Cell</i> , 1999 , 97, 133-44	56.2	1008
3	Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 414-20		58
2	Severe infections in plasmapheresis-treated systemic lupus erythematosus 1998 , 41, 414		2
1	High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1423-30		87